What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?

Not all post-protocol therapy was reported; however, nearly 20% of patients who were treated with pirtobrutinib on trial went on to receive CAR-T therapy. Pirtobrutinib’s ideal use is dependent on patient and disease characteristics. In the BRUIN trial, the median PFS, DOR, and OS of MCL patients wa...

There is limited data on the outcomes of patients following pirtobrutinib but clinically, we have used this drug as a bridge to CAR-T in younger healthier patients, and for older frailer patients, we have used this drug until progression. With a rapidly evolving landscape in MCL, the role of these a...